Cofoe Medical Technology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022	Dec '20 Dec 31, 2020
Operating Revenue	2,991	2,842	2,706	2,869	2,129	2,324
Other Revenue	141.38	141.38	148.02	108.05	146.74	51.66
Revenue	3,132	2,983	2,854	2,977	2,276	2,375
Revenue Growth (YoY)	5.16%	4.53%	-4.14%	30.82%	-4.19%	62.46%
Cost of Revenue	1,493	1,468	1,670	1,839	1,296	1,376
Gross Profit	1,639	1,515	1,184	1,137	979.57	999.13
Selling, General & Admin	1,226	1,095	851.63	740.79	471.08	483.56
Research & Development	88.09	96.41	114.33	118.42	70.59	43.11
Other Operating Expenses	10.21	8.88	8.18	12.65	6.24	-0.36
Operating Expenses	1,327	1,205	973.55	886.23	558.69	529.48
Operating Income	311.63	309.73	210.31	251.23	420.89	469.65
Interest Expense	-15.81	-17.91	-13.5	-10.85	-6.81	-1.44
Interest & Investment Income	43.95	54.71	82.02	102.64	14.41	8.3
Earnings From Equity Investments	-	-	-	-	-	-1.43
Currency Exchange Gain (Loss)	0.52	0.52	0.16	0.36	-0.19	-0.1
Other Non Operating Income (Expenses)	-0.61	-1.9	-3.27	-2.49	-0.44	-2.06
EBT Excluding Unusual Items	339.69	345.15	275.71	340.89	427.86	472.91
Impairment of Goodwill	-	-	-	-0.15	-	-
Gain (Loss) on Sale of Investments	20.8	9.4	-1.56	4.4	6.02	-
Gain (Loss) on Sale of Assets	5.24	5.88	4.59	6.47	0.14	0.22
Asset Writedown	1.61	-2.32	-2.24	-35.14	-0.05	-0.01
Legal Settlements	2.19	2.19	-2.41	-	-0.16	-
Other Unusual Items	11.69	11.69	11.61	17.91	74.51	26.9
Pretax Income	381.22	372	285.71	334.39	508.33	500.02
Income Tax Expense	61.31	59.66	32.84	32.37	78.74	75.48
Earnings From Continuing Operations	319.91	312.34	252.87	302.02	429.59	424.54
Minority Interest in Earnings	0.14	-0.59	1.41	-0.34	-0.73	-0.59
Net Income	320.05	311.75	254.28	301.68	428.86	423.95
Net Income to Common	320.05	311.75	254.28	301.68	428.86	423.95
Net Income Growth	21.12%	22.60%	-15.71%	-29.65%	1.16%	242.76%
Shares Outstanding (Basic)	203	204	205	208	165	156
Shares Outstanding (Diluted)	203	206	205	208	165	156
Shares Change (YoY)	0.58%	0.46%	-1.70%	26.56%	5.47%	0.08%
EPS (Basic)	1.58	1.53	1.24	1.45	2.60	2.72
EPS (Diluted)	1.57	1.51	1.24	1.45	2.60	2.72
EPS Growth	20.16%	21.77%	-14.48%	-44.23%	-4.25%	242.51%
Free Cash Flow	633.9	542.9	20.6	-540.87	-273.25	122.2
Free Cash Flow Per Share	3.12	2.64	0.10	-2.60	-1.66	0.78
Dividend Per Share	1.800	1.800	1.200	1.200	1.231	-
Dividend Growth	-	50.00%	-	-2.50%	-	-
Gross Margin	52.33%	50.79%	41.48%	38.21%	43.05%	42.06%
Operating Margin	9.95%	10.38%	7.37%	8.44%	18.50%	19.77%
Profit Margin	10.22%	10.45%	8.91%	10.13%	18.85%	17.85%
Free Cash Flow Margin	20.24%	18.20%	0.72%	-18.17%	-12.01%	5.15%
EBITDA	426.65	411.31	293.98	292.34	449.78	486.09
EBITDA Margin	13.62%	13.79%	10.30%	9.82%	19.77%	20.46%
D&A For EBITDA	115.02	101.58	83.67	41.11	28.89	16.44
EBIT	311.63	309.73	210.31	251.23	420.89	469.65
EBIT Margin	9.95%	10.38%	7.37%	8.44%	18.50%	19.77%
Effective Tax Rate	16.08%	16.04%	11.49%	9.68%	15.49%	15.10%
Revenue as Reported	3,132	2,983	2,854	2,977	2,276	2,375
Advertising Expenses	-	225.57	206.59	151.96	86.71	97.51

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.